SCHEMBL30596044

SCHEMBL30596044

Cc1cccc(F)c1-n1nc2c(-c3cnc(N4CCN(C)CC4)nc3)n[nH]c2cc1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS O95271 3/20 0.44
MAP4K1 Q92918 10/20 0.42
ACVR1 Q04771 3/20 0.37
FGFR1 P11362 2/20 0.37
FGFR2 P21802 2/20 0.37
FGFR3 P22607 2/20 0.37
BMPR1A P36894 1/20 0.37
TGFBR1 P36897 1/20 0.37
ACVRL1 P37023 1/20 0.37
PIM1 P11309 2/20 0.36
USP2 O75604 2/20 0.35
ALDH1A1 P00352 2/20 0.35
CYP1A2 P05177 2/20 0.35
HIF1A Q16665 2/20 0.35
HSD17B10 Q99714 2/20 0.35
CYP3A4 P08684 1/20 0.35
ALOX15 P16050 1/20 0.35
TSHR P16473 1/20 0.35
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24418389 1.00 TNKS (0.44) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL24418405 0.91 AOC3 (0.36) TNKSMAP4K1PIM1USP2ALDH1A1
SCHEMBL30595999 0.91 AOC3 (0.36) TNKSMAP4K1PIM1USP2ALDH1A1
SCHEMBL30596003 0.90 MAP4K1 (0.42) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL24418439 0.90 MAP4K1 (0.42) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL24418315 0.90 TNKS (0.46) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL29606913 0.90 TNKS (0.46) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL24418394 0.89 MAP4K1 (0.49) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL29607018 0.89 MAP4K1 (0.49) TNKSMAP4K1ACVR1FGFR1FGFR2
SCHEMBL24418321 0.88 MAP4K1 (0.40) MAP4K1ALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223759-B1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO LTD (CN) 2025-06-11 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PDXK, CMPK1, GCK TNKS 200/4885MAP4K1 156/4885ACVR1 2808/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.